Anna Radominska-pandya PhD

Dr. Anna Radominska-Pandya received her Master’s degree from the University of Warsaw, and Ph.D. from the Institute of Biochemistry and Biophysics, Polish Academy of Sciences in Warsaw, Poland. She completed her postdoctoral training in Molecular Biology at Ohio State University in Columbus. She began her career as a Research Scientist, and later an Assistant Professor, in the area of Gastroenterology at the University of Texas Medical School. Dr. Radominska-Pandya has received ten R01 grants from the NIH and numerous other awards from funding institutions such as NSF, DoD, BRIN, and Tobacco Supplement funds (both directly and via the Arkansas Breast Cancer Research Program). She has published 160 papers in peer-reviewed journals in addition to 11 book chapters and 173 abstracts, and 9 issued and provisional patents. She is also a member of the UAMS Nanomedicine Center where she is the leader of ongoing collaborative research in the area of Nano-genetics.

Dr. Radominska_Pandya has been a member of NIH review panels since 1993. For 9 years, she was a member of two NIH study sections, Pharmacology, XNDA, and the Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Pre and Postdoctoral Fellows Study Sections. Recently, she was selected as Editor-in-Chief for Drug Metabolism Review.

Dr. Radominska_Pandya's research interests include Structure-function relationship studies of human UGTs; Regulation of human UGTs; Roles of UGTs and lipids as anti-proliferative agents in various cancer models; Suppression of human UGTs in cancer cells; Interactions between UGTs and Cannabinoid Receptors and their combined role in cancer prevention and treatment; Delivering UGT genes, and/or drugs into cancer cells using nanomaterial as delivery agents; and Roles of UGTs in the biotransformation of drugs.